8:
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.
N Engl J Med. 2005 Sep 29;353(13):1332-41.
PMID: 16192478 [PubMed - indexed for MEDLINE]
Related Articles
10:
Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL; Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group.
Am J Respir Crit Care Med. 2007 Sep 1;176(5):483-90. Epub 2007 Jun 7.
PMID: 17556722 [PubMed - indexed for MEDLINE]
Related Articles
16:
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group.
Lancet. 2007 Mar 10;369(9564):836-43.
PMID: 17350452 [PubMed - indexed for MEDLINE]
Related Articles